Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Emergent BioSolutions Inc

EBS ✗ NOT COMPLIANT ☆ Track — members

NYSE · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$4.59

▲ +2.23%

Market Cap $235.34M · Vol 257.28K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$235.34M

Micro Cap

Div Yield

N/A

EPS Growth

-76.47%

YoY

RSI (14)

15.05

Momentum

Beta

2.25

vs Market

52W High

$14.05

67.33% below

52W Low

$4.37

5.03% above

Volume

257.28K

Avg 277.03K

P/B

1.23

Price-to-book

ROE

17.27%

Return on equity

Free Float

95.75%

Public shares

Shariah Compliance8 STANDARDS

✗ Emergent BioSolutions Inc (EBS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EBS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.17%

-38.80%

-44.09%

-57.62%

YTD

-62.86%

-47.96%

-11.56%

-92.55%

Financials & Valuation

TTM · Annual

Total Revenue	$742.90M
Net Income	$52.60M
Revenue Growth (YoY)	+66.29%
Gross Margin	56.09%
Operating Margin	15.40%
Net Profit Margin	7.08%
ROE	17.27%
ROA · ROIC	6.11% · 8.06%

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	0.11
P/S	0.94
P/B	1.23
P/FCF	4.47
EPS Growth	-76.47%
Outstanding Shares	51.27M

Technical Indicators

50-Day SMA	$7.45
200-Day SMA	$9.41
RSI (14)	15.05
Beta	2.25
52-Week High	$14.05
52-Week Low	$4.37

Volume Today	257.28K
Avg Daily Volume (30D)	277.03K
Relative Volume	0.93x
Volatility (10D)	172.96
Volatility (30D)	107.55
Free Float	95.75%

Analyst Consensus

BUY

Current Price $4.59

Mean Target $11.00

52W Low$4.37 52W High$14.05

Current

Target

$4.37 $14.05

Current Analyst target

+139.65% upside potential · 3 analysts

Identifiers

ExchangeNYSE

FIGIBBG001SP1G40

ISINUS29089Q1058

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateOct 27, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.